Adjuvant S-1 chemotherapy after curative resection of gastric cancer by Law, AL et al.
Title Adjuvant S-1 chemotherapy after curative resection of gastriccancer
Author(s) Yeo, W; Lam, KO; Law, AL; Chiang, CL; Lee, CC; Au, KH
Citation Hong Kong Medical Journal, 2017, v. 23 n. 3, p. 315-316
Issued Date 2017
URL http://hdl.handle.net/10722/244879
Rights
Hong Kong Medical Journal. Copyright © Hong Kong Academy
of Medicine Press.; This work is licensed under a Creative
Commons Attribution-NonCommercial-NoDerivatives 4.0
International License.
315Hong Kong Med J  ⎥  Volume 23 Number 3  ⎥  June 2017  ⎥  www.hkmj.org
Adjuvant S-1 chemotherapy after curative 
resection of gastric cancer
To the Editor—In the February issue of Hong Kong 
Medical Journal, Yeo et al1 reported an informative 
study on the use of S-1 as adjunct chemotherapy 
after curative resection of gastric cancer. 
 Since the active ingredient in S-1 is the 
prodrug tegafur, to be converted to 5-fluorouracil 
(5FU), much of the toxicity reduction depends 
on the degradation of 5FU by dihydropyrimidine 
dehydrogenase (DPD) encoded by the DPYD 
gene. Loss-of-function mutations in DPYD would 
lead to excessive toxicity and, on rare occasions, 
could be fatal. This applies also to prodrugs such 
as capecitabine.2 The incidence of DPYD variants 
leading to reduced DPD activity has been estimated 
to be 3% to 5% in a western population and complete 
loss of function at 0.2%.3 A Korean study showed 
that minor allele frequency of single nucleotide 
polymorphism varies across different ethnic groups, 
being lowest in Koreans, followed closely by Chinese 
and Japanese with Caucasians having a higher level.4 
 For the 3% to 5% of patients with reduced 
DPD activity, S-1 (tegafur/gimeracil/oteracil) has 
the built-in safety factor similar to an earlier tegafur 
combination UFT (tegafur/uracil). With UFT, 
tegafur gives a level of 5FU below the conventional 
therapeutic level. Yet efficacy is achieved by uracil, 
another component of UFT, which reduces the 
activity of DPD and results in partial DPD deficiency. 
A study has revealed that patients with partial DPD 
deficiency (due to heterozygotic DPYD mutations) 
could be treated successfully by UFT.5 Presumably 
S-1 could be used similarly.
 For the 0.2% of cases with homozygous defects 
in DPYD, perhaps Prof Yeo and her colleagues have 
already provided the answer in their paper when 
they quoted a Taiwan study in which a single-dose 
pharmacokinetic study tested the tolerability of S-1 
in the individual patient.6 Using a small dose may 
appear contrary to traditional oncology practice, but 
in this particular situation it could be a practical and 
cost-effective way to avoid some alarming outcomes. 
 I declare no conflicts of interest other than 
having also used small single doses of 5FU and have 
screened out two patients with very severe toxicity 
over the past 30 years.
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Authors’ reply 
To the Editor—We thank Dr Leung for his comments. 
Fluoropyrimidine-associated toxicity occurs in 
approximately 30% of the patients who are being 
treated, and is fatal in 0.5% to 1%.1 
 While the 2016 ‘ESMO consensus guidelines 
for the management of patients with metastatic 
colorectal cancer’ recommends that “DPD testing 
before 5-FU administration remains an option but 
is not routinely recommended”,2 others have raised 
concern based on cumulative data over the past 30 
years that show DPD deficiency is strongly associated 
with severe and fatal fluoropyrimidine-induced 
toxicity.3 In particular, a recent meta-analysis 
provides robust data that show four DPYD variants, 
namely DPYD*2A, c.2846A > T, c.1679T > G, and 
c.1236G > A/Haplotype B3 to be associated with 
fluoropyrimidine toxicity.4 
 It has to be noted that apart from 5FU, other 
fluoropyrimidine compounds include capecitabine, 
UFT, and S1. Although plasma 5FU concentrations 
following capecitabine administration can be more 
affected by DPD, they vary less extensively following 
administration of DPD-inhibitory fluoropyrimidines, 
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S-1, and UFT.5 Studies have suggested that S-1 
can be safely administered to cancer patients with 
DPD deficiency because DPD is already inactivated 
by gimeracil (CDHP) when S-1 is administered.6 
Severe toxicities, however, can still be associated 
with different fluoropyrimidines and hence further 
research on the biomarkers of chemotherapy 
sensitivity and toxicity is needed. 
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